Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Buys 5,919 Shares of Stock

Posted by Casey Walker on May 19th, 2025

Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 5,919 shares of the stock in a transaction on Monday, May 19th. The stock was acquired at an average cost of $11.78 per share, with a total value of $69,725.82. Following the completion of the purchase, the director now directly owns 17,883,908 shares of the company’s stock, valued at $210,672,436.24. The trade was a 0.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

On Thursday, May 15th, Ecor1 Capital, Llc acquired 49,502 shares of Zymeworks stock. The stock was bought at an average price of $11.43 per share, for a total transaction of $565,807.86.
On Wednesday, April 16th, Ecor1 Capital, Llc bought 73,953 shares of Zymeworks stock. The shares were bought at an average price of $11.16 per share, with a total value of $825,315.48.
On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The stock was purchased at an average cost of $11.17 per share, for a total transaction of $2,194,212.46.
On Wednesday, April 2nd, Ecor1 Capital, Llc bought 74,360 shares of Zymeworks stock. The stock was acquired at an average cost of $11.85 per share, for a total transaction of $881,166.00.
On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The stock was acquired at an average price of $11.75 per share, with a total value of $51,664.75.
On Wednesday, March 26th, Ecor1 Capital, Llc purchased 43,848 shares of Zymeworks stock. The shares were bought at an average price of $12.24 per share, for a total transaction of $536,699.52.
On Monday, March 24th, Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock. The shares were acquired at an average price of $13.08 per share, for a total transaction of $296,772.12.
On Friday, March 21st, Ecor1 Capital, Llc purchased 31,033 shares of Zymeworks stock. The shares were purchased at an average price of $12.78 per share, for a total transaction of $396,601.74.
On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was acquired at an average cost of $12.64 per share, with a total value of $736,987.84.
On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were purchased at an average cost of $12.23 per share, for a total transaction of $688,267.71.

Zymeworks Price Performance

Shares of ZYME stock traded up $0.11 during trading hours on Monday, reaching $11.82. 242,872 shares of the company traded hands, compared to its average volume of 598,736. The company has a market cap of $822.40 million, a P/E ratio of -7.88 and a beta of 1.24. Zymeworks Inc. has a 12-month low of $8.21 and a 12-month high of $17.70. The firm has a 50-day moving average price of $11.82 and a 200 day moving average price of $13.38.

Zymeworks (NYSE:ZYME – Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company had revenue of $27.11 million for the quarter, compared to analysts’ expectations of $20.65 million. During the same quarter in the previous year, the company earned ($0.42) EPS. Zymeworks’s revenue for the quarter was up 170.3% on a year-over-year basis. Sell-side analysts predict that Zymeworks Inc. will post -1.39 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZYME. Lifesci Capital assumed coverage on Zymeworks in a research note on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price target for the company. Citigroup boosted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, March 7th. Finally, HC Wainwright increased their price target on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.00.

Get Our Latest Analysis on ZYME

Hedge Funds Weigh In On Zymeworks

A number of hedge funds have recently made changes to their positions in ZYME. EcoR1 Capital LLC grew its stake in Zymeworks by 14.8% during the first quarter. EcoR1 Capital LLC now owns 17,259,548 shares of the company’s stock valued at $205,561,000 after acquiring an additional 2,231,469 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Zymeworks by 184.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company’s stock valued at $46,210,000 after purchasing an additional 2,514,834 shares during the last quarter. Deutsche Bank AG boosted its stake in Zymeworks by 0.4% during the first quarter. Deutsche Bank AG now owns 1,552,612 shares of the company’s stock worth $18,492,000 after buying an additional 5,840 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Zymeworks by 14.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company’s stock worth $14,240,000 after purchasing an additional 123,240 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in shares of Zymeworks by 1.0% during the first quarter. Bridgeway Capital Management LLC now owns 766,944 shares of the company’s stock valued at $9,134,000 after buying an additional 7,291 shares during the period. Institutional investors own 92.89% of the company’s stock.

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.